AFT Pharmaceuticals Ltd. 2020 AR2
The report highlights AFT Pharmaceuticals' financial and operational performance for the fiscal year ended March 31, 2020, including breaking through 100 million NZD in sales for the first time. It outlines the company's progress in commercializing its core Maxigesic pain relief medicine globally and advancing clinical trials for its orphan drug Pascomer. The report details the company's alignment with eight United Nations Sustainable Development Goals, focusing on good health, gender equality, and reducing inequalities. Additionally, it highlights community initiatives, such as donating eye drops to Australian firefighters and supporting medical charities in developing nations.
Company: AFT Pharmaceuticals Ltd.
Sector: Manufacturing
Country: New Zealand
Year: 2020
Type: AR2
Pages: 43
Back to company
AFT Pharmaceuticals Ltd.
Annual Report
The report highlights AFT Pharmaceuticals' financial and operational performance for the fiscal year ended March 31, 2020, including breaking through 100 million NZD in sales for the first time. It outlines the company's progress in commercializing its core Maxigesic pain relief medicine globally and advancing clinical trials for its orphan drug Pascomer. The report details the company's alignment with eight United Nations Sustainable Development Goals, focusing on good health, gender equality, and reducing inequalities. Additionally, it highlights community initiatives, such as donating eye drops to Australian firefighters and supporting medical charities in developing nations.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Apr 1, 2019 - Mar 31, 2020
Fiscal Year
2020
Published
May 20, 2020
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees